MoFo Advises Krystal Biotech on $200 Million Common Stock Offering

Morrison & Foerster represented Krystal Biotech, Inc. in its $200 million common stock offering at $75 per share. Goldman Sachs & Co. LLC, BofA Securities, Cowen, and William Blair acted as joint book-running managers for the offering. Chardan acted as lead manager for the offering.

Krystal (NASDAQ: KRYS) is a clinical-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. It recently released positive topline results from the GEM-3 pivotal trial of its leading product candidate VYJUVEK™ in patients with dystrophic epidermolysis bullosa.

The MoFo deal team was led by San Francisco corporate senior counsel John Campbell and included corporate associates John Hensley, Jonathan Burr, and Joel Todd. Partner Jim Mullen and associate Bu Yin provided intellectual property counsel on the matter. MoFo has represented the company in corporate and intellectual property matters since its inception in 2016.

Read more about the offering in Krystal's press release.